Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Abstract Purpose The choice of continuous renal replacement therapy (CRRT) anticoagulation program for patients at high risk of bleeding has always been a complex problem in clinical practice. Clinical regimens include regional citrate anticoagulation (RCA) and nafamostat mesylate (NM). This study a...

Full description

Bibliographic Details
Main Authors:	Dan Liu, Jian Zhao, Hui Xia, Shi Dong, Songjuan Yan, Yugang Zhuang, Yuanzhuo Chen, Hu Peng
Format:	Article
Language:	English
Published:	BMC 2024-01-01
Series:	European Journal of Medical Research
Subjects:	Nafamostat mesylate Regional citrate anticoagulation Anticoagulation Continuous renal replacement therapy High risk of bleeding
Online Access:	https://doi.org/10.1186/s40001-024-01660-7

Similar Items

Anticoagulation application of nafamostat mesylate in patients on continuous renal replacement therapy at a high risk of hemorrhage
by: Jia-rong Ding, et al.
Published: (2024-02-01)

Comparison of circuit patency and exchange rates between the original and generic versions of nafamostat mesylate in critically ill adults receiving continuous renal replacement therapy
by: Sujung Heo, et al.
Published: (2023-03-01)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
by: Weiwei Qian, et al.
Published: (2023-09-01)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
by: Takahiro Hirayama, et al.
Published: (2017-07-01)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
by: Shinya Kameda, et al.
Published: (2023-01-01)

Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study
by: Shinya Kameda, et al.
Published: (2024-02-01)

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes
by: Yiqi Qian, et al.
Published: (2024-09-01)

Regional citrate anticoagulation for continuous renal replacement therapy in newborns
by: Haixia Huang, et al.
Published: (2023-03-01)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
by: Nobuki Shioya, et al.
Published: (2022-07-01)

Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report
by: Yasuhito Suzuki, et al.
Published: (2024-01-01)

Adverse events with regional citrate anticoagulation versus heparin anticoagulation during continuous renal replacement therapy: a systematic review and trial sequential analysis
by: Min-min Wang, et al.
Published: (2023-10-01)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
by: Yuxin Zhang, et al.
Published: (2020-08-01)

Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis
by: Wei Zhang, et al.
Published: (2019-01-01)

Anticoagulation strategies for pediatric continuous renal replacement therapy
by: Aakash Chandran Chidambaram, et al.
Published: (2024-09-01)

The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety
by: Taeil Kim, et al.
Published: (2024-07-01)

Novel blood product transfusion regimen to prevent clotting and citrate accumulation during continuous renal replacement therapy with regional citrate anticoagulation in children
by: Yuelin Sun, et al.
Published: (2023-06-01)

Citrate and low-dose heparin combined anticoagulation in pediatric continuous renal replacement therapy
by: Desheng Zhu, et al.
Published: (2024-06-01)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
by: George Zaki Ghali, et al.
Published: (2020-01-01)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
by: Jae Ha Lee, et al.
Published: (2022-05-01)

Heparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk
by: Jing Jiao, et al.
Published: (2023-12-01)

Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus
by: Shu-Yuan Liu, et al.
Published: (2023-05-01)

Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury
by: Fang Hu, et al.
Published: (2022-10-01)

Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury
by: Wenli Guo, et al.
Published: (2022-11-01)

Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice
by: Rita Jacobs, et al.
Published: (2024-10-01)

Simple citrate anticoagulation protocol for low flux haemodialysis
by: Eng Kuang Lim, et al.
Published: (2018-01-01)

Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy: Is Metabolic Fear the Enemy of Logic? A Systematic Review and Meta-Analysis of Randomised Controlled Trials
by: Rita Jacobs, et al.
Published: (2023-05-01)

Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats
by: Ji-Hyun Kang, et al.
Published: (2021-09-01)

Construction and validation of a prediction model for the risk of citrate accumulation in patients with hepatic insufficiency receiving continuous renal replacement therapy with citrate anticoagulation
by: Quxia Hong, et al.
Published: (2024-01-01)

Comparison of Citrate and Heparin for Continuous Renal Replacement Therapy in Pediatric Intensive Units
by: Edin Botan, et al.
Published: (2023-12-01)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
by: Hyeon-A Kim, et al.
Published: (2022-06-01)

Anticoagulation during continuous renal replacement therapy: An update
by: Aslanidis Theodoros, et al.
Published: (2019-01-01)

Complications of regional citrate anticoagulation: accumulation or overload?
by: Antoine G. Schneider, et al.
Published: (2017-11-01)

Safety and Metabolic Tolerance of Citrate Anticoagulation in Critically Ill Polytrauma Patients with Acute Kidney Injury Requiring an Early Continuous Kidney Replacement Therapy
by: Filippo Mariano, et al.
Published: (2023-09-01)

Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
by: Christophe Leroy, et al.
Published: (2021-01-01)

Determinants of Calcium Infusion Rate During Continuous Veno-venous Hemofiltration with Regional Citrate Anticoagulation in Critically Ill Patients with Acute Kidney Injury
by: De-Lin Liu, et al.
Published: (2016-01-01)

Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
by: Matthias Klingele, et al.
Published: (2017-11-01)

A safe and effective protocol for postdilution hemofiltration with regional citrate anticoagulation
by: Thomas Dimski, et al.
Published: (2024-07-01)

Study on the application of a segmented sodium citrate solution anticoagulation strategy in critically ill patients receiving CRRT: a prospective, randomized controlled study
by: Yu Chen, et al.
Published: (2024-08-01)

Regional citrate anticoagulation (RCA) in critically ill patients undergoing renal replacement therapy (RRT): expert opinion from the SIAARTI-SIN joint commission
by: Valentina Pistolesi, et al.
Published: (2023-03-01)

Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review
by: Willem Boer, et al.
Published: (2023-03-01)